This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
On the 26th-27th of October, Vilnius is hosting the European Forum for Industrial Biotechnology & the Bioeconomy 2022 (EFIB'22). The forum will bring together business leaders, entrepreneurs, scientists, and investors as one of Europe's most meaningful events for biotechnology. We caught up with the Executive Director of the Lithuanian Biotechnology Association, Agne Vaitkeviciene, who told us about the importance of the forum and the potential of the Lithuanian life sciences sector.
As regular readers know, the biosimilar boom for provider-administered drugs has been accelerating. Prices are dropping while adoption accelerates. In many therapeutic areas, biosimilars’ market share is approaching 80%. In the video below, I review these developments and discuss lessons from the launch of Semglee, the first interchangeable insulin.
Because Hunter syndrome is a rare, inherited disorder that mostly impacts children, it can lead to many questions from the parents and caregivers of those that are affected.
This is a guest post by Oleksandr Topachevskyi at Digital Health Outcomes. Oleksandr may be contacted at sales@digitalho.com Commercial, nonprofit, and government companies are quite good at calculating the costs…. The post Social Return on Investment appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Collaboration expands Lonza’s end-to-end offering for mRNA manufacturing with additional, differentiated source of DNA raw material, Touchlight’s doggybone DNA (dbDNATM). Touchlight provides synthetic DNA through a cell-free enzymatic process, with advantages of speed, quality, capacity, and scalability.
Today’s guest post comes from Kristina Crockett, Vice President of Product Management at CoverMyMeds. Kristina discusses the affordability challenges that patients face in our complex and confusing healthcare system. She then explains how data and technology can help payers, manufacturers, and providers improve medication access. To learn more about CoverMyMeds’ comprehensive affordability solutions, download Overcoming Medication Affordability Challenges with Patient-Centered Solutions.
Signup to get articles personalized to your interests!
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Today’s guest post comes from Kristina Crockett, Vice President of Product Management at CoverMyMeds. Kristina discusses the affordability challenges that patients face in our complex and confusing healthcare system. She then explains how data and technology can help payers, manufacturers, and providers improve medication access. To learn more about CoverMyMeds’ comprehensive affordability solutions, download Overcoming Medication Affordability Challenges with Patient-Centered Solutions.
Strong clinical trial recruitment strategies start from a place of patient centricity, incorporating a variety of outreach methods designed to educate and engage potential participants. Creating a structured clinical trial patient recruitment plan before outreach begins is a smart way to ensure that the process is organized, efficient, and keeps the patient experience as the top priority.
A well-trained, effective, and efficient team is key to a successful clinical trial. Especially in the post-COVID world of changing work modalities, implementing a training program can seem more confusing than ever. The forced exodus to all-virtual environments opened the door to more flexibility in developing and delivering training. With the changed landscape, training now has the potential for greater effectiveness and efficiency.
Salipro Biotech strengthens its IP portfolio protecting its innovative, proprietary technology to enable the development of therapeutics against challenging drug targets, including GPCR’s, SLCs and Ion Channels.
This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Italy. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Italy? appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Yes, it’s true, there may be no replacing the stir of real live face-to-face networking, or the unprompted bartering of ideas over slightly awkwardly poised coffee and finger food in the convention hall breakout space: but as many of us unfurl, de-mask and move forward in our post-COVID-19 world, one thing the pandemic has surely revealed—especially to colleagues in our stellar events teams here at Thermo Fisher Scientific—is that the virtual event format is very much a viable front-runner for e
As electronic documentation usage increases in clinical trials, organizations must make sure they’re still protecting participants’ health and safety without sacrificing quality or efficacy. One way to do so is to ensure the software platforms you are using to conduct research are in line with federal regulations. Computer systems used for clinical trials fall under Food and Drug Administration (FDA) 21 CFR Part 11.
The recent class action lawsuit against Mars Inc. for their use of titanium dioxide in Skittles has many people wondering why the chemical is used as a food additive in the first place, if it is safe to consume, and what the alternatives are if corporations decide or are compelled to phase it out. Three Halo scientists provide very different perspectives on why titanium dioxide seems to be so difficult to replace.
Annual Drug Patent Expirations for POSIMIR Posimir is a drug marketed by Innocoll and is included in one NDA. It is available from one supplier. There are four patents protecting…. The post New patent for Innocoll drug POSIMIR appeared first on DrugPatentWatch - Make Better Decisions.
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
In the past, components of adaptive immunity were thought to play non-overlapping roles in antimicrobial host defense, with antibodies targeting pathogens in the extracellular environment and T cells responsible for eliminating intracellular infections. However, a recent study has shattered this perception. Researchers at Cincinnati Children’s Hospital Medical Center published a research paper in Nature titled: Pregnancy enables antibody protection against intracellular infection.
This is a guest post by Luther Munford , Butler Snow LLP , who comes to us fresh from the pelvic mesh wars. He is grateful to Jin Yoshikawa of that firm for his help with this post. As always, our guest posters do their own work and thus deserve 100% of the credit (and any blame) for what they write. *. As previously stated , Medtronic, Inc. v. Lohr , 518 U.S. 470 (1996), has nothing useful to say about the FDA’s current system for clearing medical devices.
Annual Drug Patent Expirations for PHEXXI Phexxi is a drug marketed by Evofem Inc and is included in one NDA. It is available from one supplier. There are two patents…. The post New patent for Evofem Inc drug PHEXXI appeared first on DrugPatentWatch - Make Better Decisions.
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
This chart shows the pharmaceutical companies with the most patents in Bulgaria. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Bulgaria? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for KYNMOBI Kynmobi is a drug marketed by Sunovion Pharms Inc and is included in one NDA. It is available from one supplier. There are eighteen…. The post New patent for Sunovion Pharms drug KYNMOBI appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for LOKELMA Lokelma is a drug marketed by Astrazeneca and is included in one NDA. It is available from one supplier. There are twelve patents protecting…. The post New patent for Astrazeneca drug LOKELMA appeared first on DrugPatentWatch - Make Better Decisions.
This chart shows the pharmaceutical companies with the most patents in Netherlands. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical companies have the most drug patents in Netherlands? appeared first on DrugPatentWatch - Make Better Decisions.
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Annual Drug Patent Expirations for GALAFOLD Galafold is a drug marketed by Amicus Therap Us and is included in one NDA. There are forty-four patents protecting this drug. This drug…. The post New patent for Amicus Therap drug GALAFOLD appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for EXPAREL Exparel is a drug marketed by Pacira Pharms Inc and is included in one NDA. It is available from one supplier. There are six…. The post New patent for Pacira Pharms drug EXPAREL appeared first on DrugPatentWatch - Make Better Decisions.
This chart shows the drugs with the most supplementary protection certificates (SPCs). SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating for the long…. The post Which drugs have the most supplementary protection certificates? appeared first on DrugPatentWatch - Make Better Decisions.
Annual Drug Patent Expirations for LONHALA+MAGNAIR+KIT Lonhala Magnair Kit is a drug marketed by Sunovion Resp and is included in one NDA. It is available from one supplier. There are…. The post New patent expiration for Sunovion Resp drug LONHALA MAGNAIR KIT appeared first on DrugPatentWatch - Make Better Decisions.
This chart shows the drugs with the most patents in Luxembourg. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Luxembourg? appeared first on DrugPatentWatch - Make Better Decisions.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
113 
Let's personalize your content